Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/49725
DC FieldValueLanguage
dc.contributor.authorRaccah, Denis
dc.contributor.authorLin, Jay
dc.contributor.authorWang, Edward
dc.contributor.authorGermé, Maeva
dc.contributor.authorPerfetti, Riccardo
dc.contributor.authorBonadonna, Riccardo C.
dc.contributor.authorDe Pablos-Velasco, Pedro
dc.contributor.authorRoussel, Ronan
dc.contributor.authorRosenstock, Julio
dc.date.accessioned2018-11-24T10:12:20Z-
dc.date.available2018-11-24T10:12:20Z-
dc.date.issued2014
dc.identifier.issn1056-8727
dc.identifier.urihttp://hdl.handle.net/10553/49725-
dc.description.abstractAims: To compare the efficacy and safety of lixisenatide (LIXI), a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist, as add-on to basal insulin (Basal + LIXI) versus once-daily rapid-acting insulin (Basal + RAI) in patients with type 2 diabetes mellitus (T2DM).Methods: Data were extracted from five randomized controlled trials assessing the efficacy and safety of basal insulin + insulin glulisine (n = 3) or basal insulin + LIXI (n = 2). Patients in the Basal + LIXI cohort were matched to patients in the Basal + RAI cohort using propensity score matching.Results: In the matched population, Basal + LIXI was twice as likely to reach composite outcomes of glycated haemoglobin (HbA(1c)) <7% and no symptomatic hypoglycaemia compared with the Basal + RAI group (odds ratio [OR]: 1.90; 95% confidence interval [CI]: 1.01, 3.55; P = 0.0455), as well as HbA(1c) <7% and no severe hypoglycaemia (OR: 1.97; 95 CI: 1.06, 3.66; P = 0.0311). Furthermore, Basal + LIXI was more than twice as likely to reach HbA(1c) <7%, no weight gain and no symptomatic hypoglycaemia (OR: 2.58; 95% CI: 1.23, 5.40; P = 0.0119).Conclusions: Both basal + LIXI and Basal + RAI improved glycaemic control in patients with T2DM with inadequate glycaemic control on basal insulin. Basal + LIXI offers an effective therapeutic option to advance basal insulin therapy, improving glucose control without weight gain and with less risk of hypoglycaemia than prandial insulin. (C) 2014 Published by Elsevier Inc.
dc.publisher1056-8727
dc.relation.ispartofJournal of Diabetes and its Complications
dc.sourceJournal of Diabetes and its Complications[ISSN 1056-8727],v. 28, p. 40-44
dc.subject.otherEuropean-Association
dc.subject.otherGlycemic Control
dc.subject.otherTherapy
dc.subject.otherManagement
dc.subject.otherHyperglycemia
dc.subject.otherGlucose
dc.subject.otherIntensification
dc.subject.otherInitiation
dc.subject.otherStatement
dc.subject.otherGlargine
dc.titleOnce-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: Analysis of data from five randomized, controlled trials
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1016/j.jdiacomp.2013.10.003
dc.identifier.scopus84891835082
dc.identifier.isi000329592100010
dc.contributor.authorscopusid7006623032
dc.contributor.authorscopusid57203632144
dc.contributor.authorscopusid55744875300
dc.contributor.authorscopusid55924266100
dc.contributor.authorscopusid55347823300
dc.contributor.authorscopusid7006221309
dc.contributor.authorscopusid6603805479
dc.contributor.authorscopusid16204234300
dc.contributor.authorscopusid7006091173
dc.description.lastpage44
dc.description.firstpage40
dc.relation.volume28
dc.type2Artículoes
dc.contributor.daisngid30315162
dc.contributor.daisngid4346353
dc.contributor.daisngid6541184
dc.contributor.daisngid2634131
dc.contributor.daisngid267918
dc.contributor.daisngid71862
dc.contributor.daisngid739699
dc.contributor.daisngid58845
dc.contributor.daisngid12324
dc.contributor.wosstandardWOS:Raccah, D
dc.contributor.wosstandardWOS:Lin, J
dc.contributor.wosstandardWOS:Wang, E
dc.contributor.wosstandardWOS:Germe, M
dc.contributor.wosstandardWOS:Perfetti, R
dc.contributor.wosstandardWOS:Bonadonna, RC
dc.contributor.wosstandardWOS:de Pablos-Velasco, P
dc.contributor.wosstandardWOS:Roussel, R
dc.contributor.wosstandardWOS:Rosenstock, J
dc.date.coverdateEnero 2014
dc.identifier.ulpgces
dc.description.sjr1,001
dc.description.jcr3,005
dc.description.sjrqQ1
dc.description.jcrqQ2
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptRendimiento humano, ejercicio físico y salud-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptCiencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-9190-2581-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameDe Pablos Velasco, Pedro Luis-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

34
checked on Jul 18, 2021

WEB OF SCIENCETM
Citations

29
checked on Jul 18, 2021

Page view(s)

8
checked on Jun 27, 2021

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.